Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1997; 29:1102-1106
© 1997 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shou, M
Right arrow Articles by Unger, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shou, M
Right arrow Articles by Unger, E.

Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels

M Shou, V Thirumurti, S Rajanayagam, DF Lazarous, E Hodge, JA Stiber, M Pettiford, E Elliott, SM Shah, and EF Unger

Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1650, USA.

OBJECTIVES: We sought to evaluate the potential of basic fibroblast growth factor (bFGF) to enhance coronary collateral perfusion in dogs with chronic single-vessel coronary occlusion. A secondary goal was to examine whether the salutary effects of bFGF treatment, previously proved effective in the short term, would be maintained in the long term (6 months). BACKGROUND: bFGF, an angiogenic growth factor, is currently the subject of a Phase I trial in patients with ischemic heart disease. It has been shown to promote collateral development in dogs with progressive coronary occlusion when given during the period of natural collateralization. The effect of bFGF on quiescent collateral vessels, a subject of significant clinical importance, is uncertain. METHODS: Dogs were subjected to ameroid-induced occlusion of the left circumflex coronary artery and randomized to bFGF (1.74 mg/day for 7 days), a regimen previously proved effective, or to saline solution. Maximal collateral perfusion was assessed 6 months later, and the dogs were reassigned to a course of bFGF or saline solution. Collateral perfusion was reevaluated after the second treatment course. RESULTS: At 6 months, collateral function was identical in the groups treated initially with bFGF and saline solution. The subsequent course of bFGF did not induce further collateralization. CONCLUSIONS: Although we previously demonstrated the salutary effects of this bFGF regimen in the short term (5 weeks), collateral flow in control dogs reached parity with that of bFGF-treated dogs after 6 months. bFGF did not induce further collateralization in dogs with mature collateral vessels, underscoring the priming role of ischemia for bFGF-induced collateral development.


This article has been cited by other articles:


Home page
Vasc MedHome page
C Kalka and I. Baumgartner
Gene and stem cell therapy in peripheral arterial occlusive disease
Vascular Medicine, May 1, 2008; 13(2): 157 - 172.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
R. W. Seidler, M. C. Lenter, B. D. Guth, and H. Doods
Short-Term Intra-Arterial Infusion of Monocyte Chemoattractant Protein-1 Results in Sustained Collateral Artery Growth
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 61 - 68.
[Abstract] [PDF]


Home page
Circ. Res.Home page
G. Suzuki, T.-C. Lee, J. A. Fallavollita, and J. M. Canty Jr
Adenoviral Gene Transfer of FGF-5 to Hibernating Myocardium Improves Function and Stimulates Myocytes to Hypertrophy and Reenter the Cell Cycle
Circ. Res., April 15, 2005; 96(7): 767 - 775.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
N. M. Degabriele, U. Griesenbach, K. Sato, M. J. Post, J. Zhu, J. Williams, P. K. Jeffery, D. M. Geddes, and E. W. F. W. Alton
Critical appraisal of the mouse model of myocardial infarction
Exp Physiol, July 1, 2004; 89(4): 497 - 505.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. Ueyama, G. Bing, Y. Tabata, M. Ozeki, K. Doi, K. Nishimura, H. Suma, and M. Komeda
Development of biologic coronary artery bypass grafting in a rabbit model: Revival of a classic concept with modern biotechnology
J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1608 - 1615.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C.-E. Luyt, A. Meddahi-Pelle, B. Ho-Tin-Noe, S. Colliec-Jouault, J. Guezennec, L. Louedec, H. Prats, M.-P. Jacob, M. Osborne-Pellegrin, D. Letourneur, et al.
Low-Molecular-Weight Fucoidan Promotes Therapeutic Revascularization in a Rat Model of Critical Hindlimb Ischemia
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 24 - 30.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Funatsu, Y. Sawa, S. Ohtake, T. Takahashi, G. Matsumiya, N. Matsuura, T. Nakamura, and H. Matsuda
Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor
J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1099 - 1105.
[Abstract] [Full Text]


Home page
ANN INTERN MEDHome page
S. B. Freedman and J. M. Isner
Therapeutic Angiogenesis for Coronary Artery Disease
Ann Intern Med, January 1, 2002; 136(1): 54 - 71.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E.-J. Kim, R.-K. Li, R. D. Weisel, D. A.G. Mickle, Z.-Q. Jia, S. Tomita, T. Sakai, and T. M. Yau
Angiogenesis by endothelial cell transplantation
J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 963 - 971.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. F Unger
Experimental evaluation of coronary collateral development
Cardiovasc Res, February 16, 2001; 49(3): 497 - 506.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
I. E. Hoefer, N. van Royen, I. R. Buschmann, J. J. Piek, and W. Schaper
Time course of arteriogenesis following femoral artery occlusion in the rabbit
Cardiovasc Res, February 16, 2001; 49(3): 609 - 617.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Fujita
Heparin and angiogenic therapy
Eur. Heart J., February 2, 2000; 21(4): 270 - 274.
[PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. J. Laham, M. Rezaee, M. Post, D. Novicki, F. W. Sellke, J. D. Pearlman, M. Simons, and D. Hung
Intrapericardial Delivery of Fibroblast Growth Factor-2 Induces Neovascularization in a Porcine Model of Chronic Myocardial Ischemia
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 795 - 802.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
J. R Kersten, P. S Pagel, W. M Chilian, and D. C Warltier
Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia
Cardiovasc Res, July 1, 1999; 43(1): 44 - 57.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
T. Hasegawa, A. Kimura, M. Miyataka, M. Inagaki, and K. Ishikawa
Basic Fibroblast Growth Factor Increases Regional Myocardial Blood Flow and Salvages Myocardium in the Infarct Border Zone in a Rabbit Model of Acute Myocardial Infarction
Angiology, June 1, 1999; 50(6): 487 - 495.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. J. Laham, M. Simons, M. Tofukuji, D. Hung, and F. W. Sellke
MODULATION OF MYOCARDIAL PERFUSION AND VASCULAR REACTIVITY BY PERICARDIAL BASIC FIBROBLAST GROWTH FACTOR: INSIGHT INTO ISCHEMIA-INDUCED REDUCTION IN ENDOTHELIUM-DEPENDENT VASODILATATION
J. Thorac. Cardiovasc. Surg., December 1, 1998; 116(6): 1022 - 1028.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Melillo, M. Scoccianti, I. Kovesdi, J. Safi Jr, T. Riccioni, and M. C Capogrossi
Gene therapy for collateral vessel development
Cardiovasc Res, September 1, 1997; 35(3): 480 - 489.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement